Improving treatments for chronic lymphocytic leukemia when current medicines stop working
Understanding mechanisms of BTK inhibitor and degrader resistance in patients with chronic lymphocytic leukemia
['FUNDING_R01'] · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · NIH-11128567
This research aims to discover why some chronic lymphocytic leukemia patients stop responding to new medications, so we can find better ways to help them.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (CORAL GABLES, UNITED STATES) |
| Trial ID | NIH-11128567 on ClinicalTrials.gov |
What this research studies
Many patients with B-cell cancers like chronic lymphocytic leukemia (CLL) benefit from medicines called BTK inhibitors, but sometimes these treatments stop working or cause side effects. Newer, more targeted BTK inhibitors are being tested in clinical trials to address these issues. However, even with these new drugs, some patients still don't respond or their cancer returns. Our goal is to understand why these new treatments fail for some patients and to develop better strategies, including new drug combinations, to overcome this resistance. We are looking closely at the cancer cells to see what changes occur that allow them to resist treatment.
Who could benefit from this research
Good fit: Patients with chronic lymphocytic leukemia or other B-cell malignancies who have experienced their BTK inhibitor treatment becoming less effective or who are considering new treatment options might be interested in this research.
Not a fit: Patients whose chronic lymphocytic leukemia responds well to current BTK inhibitors and who do not experience resistance may not directly benefit from this specific research focus.
Why it matters
Potential benefit: If successful, this work could lead to more effective and lasting treatments for patients with chronic lymphocytic leukemia whose current therapies are no longer working.
How similar studies have performed: While BTK inhibitors have shown success, understanding and overcoming resistance to the newer non-covalent forms is an active and evolving area of research.
Where this research is happening
CORAL GABLES, UNITED STATES
- UNIVERSITY OF MIAMI SCHOOL OF MEDICINE — CORAL GABLES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TAYLOR, JUSTIN — UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
- Study coordinator: TAYLOR, JUSTIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.